Trump Unveils Healthcare Plan Aimed at Reducing Costs for Americans   Summary: Trump’s Healthcare Plan to Lower Costs and Increase Transparency President Donald Trump unveiled a comprehensive healthcare proposal aimed at lowering prescription drug prices and insurance premiums. The plan focuses on sending healthcare subsidy money directly to consumers instead of insurance companies. It proposes codifying the “Most-Favored-Nation” drug pricing policy to match U.S. drug prices with the lowest prices paid globally. Prescription drug costs could be reduced by up to 80–90% under international price benchmarking. The plan expands access to safe, verified over-the-counter medications to reduce healthcare expenses and doctor visits. Insurance premiums would be lowered by ending excess subsidies and kickbacks to insurers, PBMs, and brokerage middlemen. Funding the Cost Sharing Reduction program could cut Obamacare plan premiums by 10–15%, according to the CBO. A new “Plain English Insurance” standard would require clear, consumer-friendly disclosures from insurers. Insurance companies must publish claim denial rates, profit margins, and average care wait times. Hospitals and insurers accepting Medicare or Medicaid would be required to publicly display all prices and fees. The plan emphasizes price transparency to prevent surprise medical bills and increase competition. President Trump is urging Congress to pass the plan quickly to provide immediate financial relief to Americans. Trump Announces Healthcare Plan Designed to Lower Costs Nationwide   President Donald Trump has unveiled a sweeping healthcare proposal designed to lower prescription drug prices, reduce health insurance premiums, and expand price transparency across the U.S. healthcare system. The plan, which Trump is urging Congress to pass, aims to shift financial power away from insurers and pharmaceutical middlemen and place it directly into the hands of American consumers. Dubbed “The Great Healthcare Plan,” the proposal builds on policies from Trump’s first term while introducing new measures intended to increase competition, reduce wasteful spending, and hold insurance companies accountable. Direct Payments to Consumers, Not Insurers A central pillar of the plan is redirecting federal healthcare subsidies away from insurance companies and instead sending money directly to eligible Americans. Trump argues this approach would give individuals greater control over their healthcare decisions while reducing premium costs. Under the proposal, consumers would receive funds to purchase health insurance plans that best meet their needs, rather than relying on insurer-driven options tied to government subsidies. Lower Prescription Drug Prices Through Global Benchmarking The plan calls on Congress to codify Trump’s Most-Favored-Nation (MFN) drug pricing framework. This policy would require the United States to pay no more for prescription drugs than the lowest price paid by other developed nations. According to Trump, this approach could reduce the cost of certain medications by as much as 80–90%, reversing decades in which Americans paid the highest drug prices globally. Existing voluntary pricing agreements negotiated with the Department of Health and Human Services would remain in effect. The proposal also expands access to verified, safe pharmaceutical drugs for over-the-counter purchase, reducing the need for doctor visits and increasing consumer choice. Reducing Insurance Premiums and Government Waste To further lower premiums, the plan proposes ending what Trump describes as excessive government payments to insurance companies, pharmacy benefit managers (PBMs), and brokerage middlemen. These savings would be redirected to consumers. The proposal also fully funds the Cost Sharing Reduction (CSR) program, a long-standing component of the Affordable Care Act. According to the Congressional Budget Office, this measure alone could reduce premiums on popular marketplace plans by 10–15% while saving taxpayers an estimated $36 billion. Holding Insurance Companies Accountable The Great Healthcare Plan introduces a new “Plain English Insurance” standard requiring insurers to clearly disclose coverage details, pricing comparisons, and exclusions on their websites using simple, consumer-friendly language. Insurance companies would also be required to publish: The percentage of revenue spent on claims versus administrative costs and profits Claim denial rates and appeal outcomes Average wait times for routine care These disclosures aim to give consumers greater visibility into how insurers operate and how their premiums are used. Maximum Price Transparency Across Healthcare To eliminate surprise medical billing, the plan mandates that any hospital, healthcare provider, or insurer accepting Medicare or Medicaid must prominently display all prices and fees at their place of business. Trump argues that transparent pricing would allow patients to compare costs, shop for better care, and drive competition—ultimately lowering healthcare prices nationwide. Call to Congress President Trump has called on Congress to pass the framework without delay, emphasizing the need for immediate relief for Americans struggling with rising healthcare costs. He framed the proposal as a direct challenge to what he calls the failures of the Affordable Care Act, which he claims benefited insurers more than patients. Overview of Key Goals The Healthcare Plan aims to: Lower prescription drug prices through international price matching Reduce insurance premiums by redirecting subsidies to consumers Increase transparency in insurance and healthcare pricing Limit profiteering by insurers, PBMs, and corporate middlemen Restore consumer choice and control in healthcare decisions The proposal is expected to spark significant debate in Congress as lawmakers consider its potential economic and policy implications. This is a developing story and will be updated as further details emerge. References: https://www.whitehouse.gov/articles/2026/01/president-trump-unveils-the-great-healthcare-plan-to-lower-costs-and-deliver-money-directly-to-the-people/ https://edition.cnn.com/2026/01/15/politics/trump-health-care-plan https://www.bloomberg.com/news/articles/2026-01-15/trump-unveils-healthcare-framework-asks-congress-to-codify-it

Flu Cases Are Surging Across the United States in 2026 Flu Surge in the U.S. — Key Summary Points Flu activity has reached record-high levels across the United States this season. 8% of all medical visits were flu-related in the week ending December 27 — the highest since 1997. 120,000 hospitalizations and 5,000 deaths have been reported so far this flu season. Hospitalizations increased 48% week-over-week, signaling rapid spread. Flu test positivity jumped to 33% nationwide, up from 9% in early December. Several states, including Colorado, Utah, and Wyoming, reported positivity rates above 45%. The CDC classified flu activity as “high” nationwide and “very high” in parts of the Northeast. New York City shows slight declines, but flu levels remain very high. Michigan is experiencing a severe early surge, with pediatric ICUs treating critically ill children. A mutated Influenza A (H3N2) strain known as subclade K is driving infections. Over 90% of tested U.S. flu cases are linked to H3N2, with most identified as subclade K. Current flu vaccines may be less targeted against subclade K but still reduce severe illness. Wastewater data shows a 146% increase in flu virus concentration nationwide. Flu infections are rising in 17 states, stable in 7, and declining in 24. Common symptoms include fever, cough, fatigue, runny nose, and body aches. Health officials stress that vaccination remains the best protection, especially for children. Childhood flu vaccination rates have declined, raising public health concerns. Experts warn flu season can last until May, and it’s not too late to get vaccinated. Handwashing, staying home when sick, and mask use can help limit spread.   Flu Cases Surge Across the U.S. as New H3N2 Strain Spreads Flu activity is surging across the United States this winter, reaching levels not seen in decades. New data from the Centers for Disease Control and Prevention (CDC) shows record-high medical visits, rising hospitalizations, and growing concern among health experts as a mutated flu strain spreads nationwide. Flu Activity Reaches Historic Highs Nationwide For the first time since flu tracking began in 1997, 8% of all medical visits during the week ending December 27 were related to influenza or flu-like illness, according to the CDC. Key national highlights: 120,000 hospitalizations so far this season 5,000 flu-related deaths 48% week-over-week increase in hospital admissions Flu activity classified as “high” nationwide This marks one of the most intense early flu seasons in recent history. Flu Test Positivity Rates Climb Rapidly CDC surveillance data shows a sharp rise in flu positivity since December: 33% of flu tests were positive nationwide (23,350 out of 70,757 tests) Early December positivity was just 9% Some states exceeded 45% positivity States With Highest Positivity Rates Colorado Montana North Dakota South Dakota Utah Wyoming Northeast Reports “Very High” Flu Activity The CDC categorized flu levels as “very high” in parts of the Northeast, including: New York Massachusetts North Carolina Health officials caution that despite some localized declines, the virus remains widespread. Wastewater Data Confirms Rapid Flu Spread Wastewater surveillance from WasteWaterSCAN, a Stanford-led tracking system, reinforces CDC findings: 146% increase in flu virus concentration between early and late December Indicates broader community spread, including untested or asymptomatic cases CDC Projections: Where Flu Is Rising or Falling As of December 30: Flu cases rising in 17 states Stable or unreported in 7 states Declining or likely declining in 24 states Health officials warn trends can reverse quickly. What Is the New Flu Strain Driving This Surge? A newly dominant mutation known as subclade K is accelerating the spread. What Is Subclade K? A mutation of Influenza A (H3N2) Structurally different from previous H3N2 strains More effective at evading existing immunity CDC data shows: 91% of tested U.S. flu cases were H3N2 90.5% of those were subclade K Is the Flu Vaccine Still Effective? While the 2025–2026 flu vaccine is less targeted against subclade K, experts stress it still provides important protection. According to early international data: Hospitalization rates are similar to last season Vaccination reduces severity and complications Vaccine effectiveness remains meaningful Health authorities emphasize that vaccination still prevents severe illness and death. Common Flu Symptoms This Season Symptoms linked to H3N2 and subclade K include: Fever Cough Runny nose Fatigue Muscle aches and chills Children, older adults, and immunocompromised individuals remain at highest risk. New York City: Slight Decline, But Risk Remains High New York City health officials report early signs of decline, but warn the flu remains widespread. Key NYC data: 128,000+ flu cases this season Higher than the past two years 6% drop in childhood flu vaccinations Health Commissioner Dr. Michelle Morse warned: “We’re not out of the woods yet.” Officials stressed that flu season can last until May. Michigan Flu Surge: Pediatric Cases Raise Alarm Michigan is experiencing a severe and early flu season. Michigan Highlights: 2,110 flu-related hospitalizations 306 children under age 4 hospitalized 40% increase in hospitalizations compared to last year Pediatric ICUs reporting children on ventilators Children accounted for 69% of emergency visits for respiratory viruses during Christmas week. Doctors emphasize most severe pediatric cases involved unvaccinated children. Hospitals Report Capacity Strain Major Michigan health systems report: Rising emergency visits High inpatient occupancy Increased ICU monitoring While hospitals remain operational, officials caution that continued spread could stress resources. Why This Flu Season Is Especially Concerning Health experts cite multiple factors: Earlier seasonal peak Higher transmission rates Lower childhood vaccination coverage Co-circulation with COVID-19 and RSV Public health officials also warn about rising cases of measles and whooping cough, linked to declining vaccination rates. How to Protect Yourself and Your Family 1. Get Vaccinated Recommended for everyone 6 months and older Still effective against severe illness Not too late to get the flu shot 2. Practice Good Hygiene Wash hands with soap for 20 seconds Avoid touching face Clean high-touch surfaces 3. Stay Home When Sick Do not “push through” illness Keep sick children home from school 4. Use Masks When Necessary Especially when sick or in crowded indoor spaces When to Seek Emergency

Depo-Provera and Brain Tumors: What Patients Should Know Summary : The FDA has approved a label change for Pfizer’s birth control injection Depo-Provera, adding a warning about meningioma, a type of brain tumor. This decision reverses the FDA’s earlier rejection of a similar request in 2024. More than 2,000 women in the U.S. are suing Pfizer, alleging the company failed to warn about the risk despite decades of scientific evidence. Studies suggest women using Depo-Provera may be up to 5.5 times more likely to develop meningioma compared to non-users. Canada, the EU, and other countries have included meningioma warnings on Depo-Provera labels since 2022–2024. Plaintiffs allege Pfizer delayed or withheld safety information from U.S. regulators while providing stronger warnings overseas. The newly approved U.S. label states that meningioma cases have been reported with repeated use and advises caution for patients with prior meningioma history. A federal judge has not yet ruled on whether the lawsuits against Pfizer will proceed.   FDA Approves Brain Tumor Warning for Depo-Provera The U.S. Food and Drug Administration (FDA) has approved a significant label update for Depo-Provera, Pfizer’s injectable birth control shot. The revised labeling now warns patients and healthcare providers about a potential link between repeated use of the drug and meningioma, a tumor that forms in the lining of the brain. The approval marks a major shift in regulatory stance after the FDA previously declined to allow such a warning in 2024. What Is Depo-Provera? Depo-Provera is a progestin-based contraceptive injection administered once every three months. It contains medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone. According to the Centers for Disease Control and Prevention (CDC): About 1 in 4 sexually active women in the U.S. have used Depo-Provera. Black women use the drug at nearly twice the national average, raising concerns about disproportionate health impacts. Understanding Meningioma Risk Meningiomas are typically non-cancerous brain tumors, but they can cause serious harm depending on their size and location. Approximately 39,000 meningiomas are diagnosed annually in the U.S. Symptoms may include: Persistent headaches Vision changes Dizziness Seizures Recent research shows women using Depo-Provera may face a 5.5-fold increased risk compared to non-users. Lawsuits Against Pfizer Pfizer is currently facing lawsuits from more than 2,000 women across the United States who allege: The company knew about the potential link between progesterone-based drugs and meningioma for decades. Scientific studies dating back to 1983 suggested hormonal involvement in tumor growth. Despite this, Pfizer allegedly failed to adequately warn U.S. patients and physicians. Attorneys for the plaintiffs argue Pfizer had an “unassignable duty to investigate” and should have studied and disclosed the risks much earlier. Allegations of Delayed Warnings and Legal Strategy Court transcripts from 2025 reveal that Pfizer attempted to dismiss the lawsuits by citing the FDA’s earlier rejection of a label update, arguing that the denial carried “the force of law.” However, attorneys for the plaintiffs argue: Drug manufacturers can independently update labels using a regulatory pathway called CBE (Changes Being Effected) when safety concerns arise. Pfizer allegedly submitted an incomplete or weak request to the FDA in 2024, anticipating rejection, and then used that rejection as a legal defense. Large portions of court transcripts remain heavily redacted, particularly sections involving communications between Pfizer and regulators. FDA’s Final Decision in 2025 After Pfizer amended and resubmitted its application in June 2025, the FDA approved the warning this month. The updated label for: Depo-Provera CI Depo-Subq Provera 104 now states that: Meningioma cases have been reported with repeated use. Physicians should inform patients with a history of meningioma about the potential risk. Pfizer’s Response In a statement, Pfizer said: The label update reflects a new FDA decision. The company continues to stand by the safety and efficacy of Depo-Provera. Pfizer maintains that the lawsuits are without merit and says it will vigorously defend itself. Pfizer declined to provide interviews regarding the ongoing litigation. How Warnings Differ Around the World? United States No prior meningioma warning until now The existing black box warning focuses on bone mineral density loss No prior guidance on neurological symptom monitoring Canada Explicit meningioma warning added in 2022 Advises medical evaluation for persistent neurological symptoms European Union EMA issued formal warnings in 2022 and expanded in 2024 Recommends monitoring for meningioma symptoms Advises discontinuation if a tumor is diagnosed Notes tumors may shrink after stopping the drug Other Countries South Africa and others have also updated safety guidance for MPA-based drugs What This Means for Patients U.S. women were not warned for years about symptoms that could indicate a drug-related brain tumor. Many plaintiffs say early symptoms such as headaches and vision changes, were overlooked. The new label may help patients and doctors recognize risks sooner and make informed decisions. As one patient stated: “We deserve to know what we’re putting in our bodies.” What Happens Next A federal judge has yet to decide whether the lawsuits will proceed. Freedom of Information Act (FOIA) requests seeking full FDA-Pfizer correspondence remain unanswered. Legal experts note that similar defenses by drug manufacturers have failed in past cases. The case against Pfizer could set a major precedent for pharmaceutical transparency and patient safety in the United States. References: https://www.nbcnews.com/health/womens-health/fda-approves-label-change-depo-provera-adding-brain-tumor-warning-rcna249568 https://komonews.com/news/spotlight-on-america/legal-fight-intensifies-over-depo-provera-and-brain-tumor-allegations-drugs-pharmaceuticals-meningioma-pfizer-canada-europe-united-states-birth-control https://vocal.media/trader/fda-adds-brain-tumor-warning-to-depo-provera-as-lawsuits-against-pfizer-intensify  

New Influenza Variant Linked to Rise in Severe Flu Cases   Key Summary: New Influenza Variant (Subclade K) A new influenza A (H3N2) variant, known as subclade K, is linked to rising flu cases and hospitalizations in the U.S., Canada, the U.K., Japan, and Australia Health experts say the variant is now dominant in areas with active influenza spread Subclade K emerged after this season’s flu vaccine was developed, raising concerns about reduced vaccine match Experts stress the variant shows antigenic drift, not antigenic shift, meaning it is not considered pandemic-level The current flu vaccine may be less effective at preventing infection, but it still offers strong protection against severe illness and death CDC data shows influenza activity is increasing nationwide, with 89% of recent samples belonging to subclade K Some regions, including Texas, are seeing rising hospitalizations, especially among adults aged 65 and older Severe flu seasons can occur back-to-back, though they remain relatively uncommon Medical experts emphasize that it is not too late to get vaccinated Public health officials urge continued vaccination, monitoring of symptoms, and preventive measures     Overview: A Mutated Flu Strain Raises Global Concern Health experts are closely monitoring a new influenza A (H3N2) variant, known as subclade K, which appears to be contributing to a rise in flu cases and hospitalizations across several countries, including the United States, the United Kingdom, Canada, Japan, and Australia. Public health officials say this emerging variant may help explain why the current flu season is becoming more severe in some regions. What Is Subclade K? Subclade K is a mutated form of the H3N2 influenza A virus, a strain historically associated with more intense flu seasons. According to infectious disease experts, this variant is now dominant in areas experiencing significant influenza activity. Dr. Andrew Pekosz, a professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, said the variant is being detected widely wherever influenza is spreading in the U.S. Why Experts Are Watching This Variant Closely One major concern is that subclade K emerged after the current flu vaccine was developed, meaning the vaccine may not be a perfect match. Key concerns include: Genetic mutations that may allow the virus to partially evade immune protection Rapid spread across multiple countries Possible links to increased hospitalizations, particularly among older adults However, experts emphasize that the variant represents antigenic drift, a gradual evolutionary change, rather than antigenic shift, which is associated with pandemics.   Does the Current Flu Vaccine Still Work? While the mutations in subclade K may reduce how well the vaccine prevents infection, health experts agree the flu shot still offers important protection, especially against severe illness, hospitalization, and death. “The mutations may allow the virus to evade some—but not all—vaccine-induced protection,” Dr. Pekosz explained. He added that researchers are still determining whether the variant itself causes more severe disease or if rising severity is simply due to higher overall case numbers. Dr. Robert Hopkins, medical director of the National Foundation for Infectious Diseases, echoed this view, noting that influenza remains notoriously difficult to predict. Current Situation in the United States According to the U.S. Centers for Disease Control and Prevention (CDC), influenza activity is increasing nationwide. CDC highlights for early December: Only four states currently report high or very high flu-like illness activity 89% of flu samples collected since late September belong to subclade K National hospitalization rates remain approximately 7 per 100,000, similar to past seasons That said, some states are seeing changes. Texas, for example, has reported rising hospitalizations, particularly among people aged 65 and older, potentially linked to the new variant. Lessons From Recent Severe Flu Seasons The 2024–2025 flu season ranked among the most severe in decades. While consecutive severe seasons are uncommon, health experts stress they are not unprecedented. High circulation of aggressive strains like H3N2, combined with lower immunity and vaccine mismatches, can contribute to challenging flu years. Public Health Message: Don’t Delay Vaccination Despite uncertainties surrounding subclade K, experts agree on one point: vaccination still matters. “It is not too late to get a flu shot,” Dr. Pekosz said, stressing that even partial protection can significantly reduce serious outcomes. Public health officials continue to recommend: Getting vaccinated as soon as possible Monitoring symptoms closely, especially in older adults Practicing basic prevention, such as handwashing and staying home when ill What Happens Next? Researchers are actively studying whether subclade K leads to more severe disease on an individual level or whether its impact is primarily due to widespread transmission. As the flu season progresses toward its typical peak in January and February, health authorities say surveillance and vaccination will remain critical tools in reducing the burden of illness.

Flu-Related Deaths of Three Children in Ottawa Signal a Severe Influenza Season in Ontario   Quick Summary: Key Facts at a Glance Three children aged 5–9 have died from influenza-related complications in Ottawa and Eastern Ontario within the first two weeks of December Health officials say the deaths are unusual and may signal a severe and early flu season Influenza A (H3N2) is the dominant circulating strain and is spreading rapidly among children and teens Pediatric hospitals, including CHEO, are seeing record-high flu cases, emergency visits, and admissions Ontario ICU admissions due to influenza increased by 127% in just one week Nationwide, over 20% of flu tests are now positive, with the highest rates among people under 19 Medical experts warn that low vaccine uptake and partial strain mismatch may worsen outcomes Flu vaccination remains highly effective at preventing severe illness, hospitalization, and death Public health officials urge immediate vaccination, especially before holiday gatherings Overview: A Tragic Warning as Influenza Cases Surge Health officials in Ottawa and Eastern Ontario have confirmed the deaths of three children aged between five and nine due to influenza-related complications during the first two weeks of December. Medical officers describe the situation as unusual and alarming, highlighting concerns that the current flu season could be more aggressive than recent years. The deaths have prompted urgent warnings from Ottawa Public Health and the Eastern Ontario Health Unit, as hospitals report rapidly increasing influenza activity—particularly among children and adolescents.   Sharp Rise in Influenza A Across Ontario According to regional health authorities, there has been a rapid and significant increase in influenza A, particularly the H3N2 subtype, which is historically linked to more severe flu seasons. Key indicators include: Influenza test positivity rates exceeding 20% nationwide Ontario positivity rates nearing 26%, higher than any of the last three seasons Children under 19 account for the majority of positive cases Hospital admissions and ICU cases are rising sharply The Children’s Hospital of Eastern Ontario (CHEO) has reported exceptionally high pediatric flu cases, far exceeding seasonal norms. Pediatric Hospitals Under Pressure CHEO confirmed that: Over 300 children tested positive for influenza in the first 10 days of December Only 11 cases were recorded during the same period last year Emergency departments are seeing 220–280 visits per day Daily hospital admissions for flu-related illness continue to climb Other children’s hospitals across Toronto, Waterloo, Calgary, and Montreal report similar trends, signaling a nationwide pediatric influenza wave. ICU Admissions Jump 127% in One Week The Ontario Hospital Association reported a 127% increase in influenza-related ICU admissions in just one week. Hospitalizations rose by 84%, while confirmed flu cases increased by 150% during the same period. Health leaders stress that while COVID-19 and RSV levels remain relatively stable, influenza is now the dominant respiratory threat. Why This Flu Season Is Hitting Children Hard Experts attribute the severity to multiple overlapping factors: 1. Dominance of Influenza A (H3N2) Many children have little or no prior exposure to H3N2 Lower natural immunity increases susceptibility 2. Vaccine Mismatch Concerns The circulating strain differs genetically from vaccine strains However, vaccines still significantly reduce severe illness and hospitalization 3. Declining Vaccination Rates Public health officials report lower flu vaccine uptake Only 25% of hospitalized children in past studies were vaccinated What the Data Shows Nationwide Federal surveillance highlights troubling trends: 6,799 confirmed influenza cases in early December 1,850 flu-related hospitalizations Children aged 5–11 are showing positivity rates near 64% Teens aged 12–19 exceeding 50% positivity Health experts describe these levels as “sky-high. Vaccination Remains the Strongest Defense Despite concerns about strain mismatch, medical experts emphasize that the influenza vaccine remains highly effective at preventing severe outcomes: Up to 75% effectiveness in preventing hospital visits among children 30–40% effectiveness in adults Reduces risk of ICU admission, pneumonia, and death Since immunity takes approximately two weeks to develop, officials urge families to get vaccinated before holiday gatherings. Who Is Most at Risk? While most people recover from the flu, severe complications are more likely among: Children under five Adults over 65 Individuals with chronic illness or compromised immune systems Unvaccinated populations Health officials warn that early surges in children often precede severe outbreaks among older adults. Preventive Measures Beyond Vaccination Public health authorities recommend additional precautions: Frequent handwashing Avoiding face-touching Staying home when sick Wearing masks in healthcare settings when required Avoiding hospital and long-term care visits while ill These measures help reduce transmission during periods of high viral circulation. A Season That May Worsen Before It Improves Medical experts caution that the flu season is far from over, with peak transmission expected mid-to-late December in several regions. “The sooner you get vaccinated, the better,” experts stress, warning that continued spread could lead to more severe outcomes among vulnerable populations, including seniors in long-term care. Final Word: A Preventable Tragedy The deaths of three children in Eastern Ontario serve as a sobering reminder that influenza is not a mild illness for everyone. Health leaders emphasize that vaccination, awareness, and early action remain critical tools in preventing further loss of life during what may be one of Canada’s most challenging flu seasons in years. References: https://www.cbc.ca/news/health/kids-teens-flu-deaths-ontario-9.7018018 https://www.theglobeandmail.com/canada/article-three-children-dead-ottawa-eastern-ontario-region-flu-related/